血中波萨可纳度与血清水平之间的关系
Yuichi Shibata1, Nobuhiro Asai2, Mao Hagihara3
1Department of Infection Prevention and Control, Aichi Medical University Hospital, Nagakute, Aichi, Japan; Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Aichi, Japan.
概括
波萨可纳 (PSCZ) 可能导致低血,这是血液病患者常见的副作用. 这项研究发现PSCZ度和低血之间没有相关性,这表明无论药物水平如何,都需要保持警.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 血液学 血液学 血液学
背景情况:
- 建议对波萨科纳 (PSCZ) 进行治疗药物监测,以确定疗效.
- 很少有研究探讨了PSCZ水平和低血之间的联系,这是一个已知的不良影响.
- 这项研究研究了PSCZ度及其与低血的关联.
研究的目的:
- 测量血液病患者血清PSCZ度.
- 调查PSCZ最低度 (Cmins) 和低血之间的关系.
- 为了确定PSCZ水平是否与低血的发展或严重程度相关.
主要方法:
- 在爱知医科大学医院进行前性研究.
- 包括接受口服PSCZ的血液病患者.
- 通过高性能液态染色学测量PSCZCmins,并在60天内监测血清度.
主要成果:
- 在24名患者中,41.7%的人患有低血清症.
- 患有低血量和没有低血量患者的中位PSCZ度相似 (2.5比2.4微克/毫升).
- 在PSCZ Cmin和血清降低或最低水平之间没有发现显著的相关性.
结论:
- 波萨可纳 (PSCZ) 不论其血清度如何,都可能诱发低血.
- 血液学临床医生应保持警PSCZ患者的低血.
- 可能需要进一步的研究来阐明PSCZ诱导的低血清症的机制.
相关概念视频
Regulation of Sodium and Potassium
1.9K
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
1.9K
Time Course of Drug Effect
2.6K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.6K
Drug Concentrations: Measurements
1.0K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
1.0K
Drug Concentration Versus Time Correlation
1.9K
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
1.9K
Drug Distribution: Plasma Protein Binding
8.3K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.3K
Pharmacokinetics: Drug–Drug Interactions
329
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
329


